Announced investment in Helex Bio, gene therapies for genetic kidney disease.
OCT 2025
US- and India-based early preclinical biotechnology company developing non-viral genomic medicines for genetic kidney diseases, initially autosomal dominant polycystic kidney disease (ADPKD)
US- and India-based early preclinical biotechnology company developing non-viral genomic medicines for genetic kidney diseases, initially autosomal dominant polycystic kidney disease (ADPKD). It combines kidney-targeted lipid nanoparticle delivery with Epic-Cure, a 3D-genome-based drug design platform, to develop precise gene-editing therapeutics and support strategic partnerships.